Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein.
Nobuyoshi KosakaNobuyoshi KosakaYusuke YamamotoKagenori ItoKurataka OtsukaCarolina SoekmadjiShin EgawaTakahiro KimuraTakahiro OchiyaPublished in: Journal of extracellular vesicles (2023)
Bone metastases are still incurable and result in the development of clinical complications and decreased survival for prostate cancer patients. Recently, a number of studies have shown that extracellular vesicles (EVs) play important roles in tumour progression. Here, we show that EVs from metastatic prostate cancer cells promote osteoclast formation in the presence of receptor activator of NF-κB ligand (RANKL). EV characterization followed by functional siRNA screening identified CUB-domain containing protein 1 (CDCP1), a transmembrane protein, as an inducer of osteoclastogenesis. Additionally, CDCP1 expression on plasma-derived EVs was upregulated in bone metastatic prostate cancer patients. Our findings elucidate the effect of EVs from metastatic prostate cancer cells on osteoclast formation, which is promoted by CDCP1 located on EVs. Furthermore, our data suggested that CDCP1 expression on EVs might be useful to detect bone metastasis of prostate cancer.
Keyphrases
- prostate cancer
- bone loss
- squamous cell carcinoma
- small cell lung cancer
- binding protein
- radical prostatectomy
- poor prognosis
- protein protein
- lps induced
- nuclear factor
- amino acid
- bone mineral density
- signaling pathway
- big data
- small molecule
- immune response
- cell proliferation
- postmenopausal women
- inflammatory response
- free survival